IL4 and granular corneal dystrophy type II: This suggests the suppression of inflammation and allergic symptoms in ACD; when PSL-loaded PLGA NPs were administered under the same conditions, IL-4 was significantly reduced, confirming that allergic symptoms were suppressed.